Fact CheckerSign in

NCT06161207RecruitingPhase 3

3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer

Prospective Randomized Controlled Trials on Clinical Outcomes of Indocyanine Green Tracer Using in 3D Plus Ultra High Resolution Laparoscopic Gastrectomy With Lymph Node Dissection for Locally Advanced Gastric Cancer

Source: ClinicalTrials.gov · Last updated 24 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Patients with locally advanced gastric adenocarcinoma (CT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
702 (estimated)
First submitted
30 Nov 2023
Start date
3 Jan 2023
Primary completion date
1 Jan 2026
Lead sponsor
Fujian Medical University
NCT number
NCT06161207

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 702
  • From 3 Jan 2023 to the primary completion date, 1 Jan 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)
  • History of previous gastric surgery (including ESD/EMR for gastric cancer)
  • History of previous neoadjuvant chemotherapy or radiotherapy
  • Patients who declined laparoscopic surgery

Other illness

  • Severe mental disorder
  • Other malignant disease within the past 5 years
  • History of unstable angina or myocardial infarction within past six months
  • History of cerebrovascular accident within past six months
  • History of continuous systematic administration of corticosteroids within one month
  • Requirement for simultaneous surgery for other disease
  • Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
  • Diffuse invasive gastric cancer
  • History of an iodine allergy

Other

  • Women during pregnancy or breast-feeding
  • Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging
  • FEV1 (forced expiratory volume in one second)\<50% of predicted values

Who the study is looking for

  • Age from 18 to 75 years
  • Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
  • cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
  • No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations
  • Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale
  • ASA (American Society of Anesthesiology) class I to III
  • Written informed consent

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fujian Medical University Union Hospital
Coordinator of this site? Confirm its status
FuzhouChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.